Lenvatinib for patients with BCLC stage B2/B3 hepatocellular carcinoma: interim analysis of a multicentre prospective observational study

DOI Web Site Web Site 5 References
  • Kobayashi Satoshi
    Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center
  • Morimoto Manabu
    Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center
  • Numata Kazushi
    Gastroenterological Center, Yokohama City University Medical Center
  • Moriya Satoshi
    Gastroenterological Center, Yokohama City University Medical Center
  • Kagawa Takehiro
    Department of Gastroenterology, Tokai University
  • Uojima Haruki
    Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine
  • Hidaka Hisashi
    Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine
  • Matsunaga Kotaro
    Department of Internal Medicine, Division of Gastroenterology and Hepatology St. Marianna University School of Medicine
  • Suzuki Michihiro
    Department of Internal Medicine, Division of Gastroenterology and Hepatology St. Marianna University School of Medicine
  • Tanaka Katsuaki
    Department of Gastroenterology, Japanese Red Cross Hadano Hospital
  • Kanagawa Liver Study Group

Bibliographic Information

Other Title
  • BCLC stage B2またはB3の肝細胞癌に対するレンバチニブの多施設共同前向き観察研究の中間報告
  • BCLC stage B2 マタワ B3 ノ カン サイボウ ガン ニ タイスル レンバチニブ ノ タシセツ キョウドウ マエムキ カンサツ ケンキュウ ノ チュウカン ホウコク

Search this article

Abstract

<p>Lenvatinib (LEN) is a standard of care for patients with advanced hepatocellular carcinoma that has a high objective response rate (ORR). However, LEN is indicated only for patients with reserved liver function. We, therefore, posited that using LEN in **** (BCLC) stage B2 or B3 may be beneficial and conducted a prospective observational study in this context. In this paper, we report the results of that study in 15 initial patients. Three patients terminated LEN at 4.9 months of the median observation period, two because of disease progression and one because of an adverse event. The objective response rate (ORR) was 13% and 67% in response evaluation criteria in solid tumors (RESCIT) v1.1 and modified response evaluation criteria in solid tumors (mRECIST), respectively. We wish to continue the study to confirm survival benefits.</p>

Journal

  • Kanzo

    Kanzo 61 (5), 273-275, 2020-05-01

    The Japan Society of Hepatology

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top